Cargando…

Multiple low dose therapy as an effective strategy to treat EGFR inhibitor-resistant NSCLC tumours

Resistance to targeted cancer drugs is thought to result from selective pressure exerted by a high drug dose. Partial inhibition of multiple components in the same oncogenic signalling pathway may add up to complete pathway inhibition, while decreasing the selective pressure on each component to acq...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fernandes Neto, João M., Nadal, Ernest, Bosdriesz, Evert, Ooft, Salo N., Farre, Lourdes, McLean, Chelsea, Klarenbeek, Sjoerd, Jurgens, Anouk, Hagen, Hannes, Wang, Liqin, Felip, Enriqueta, Martinez-Marti, Alex, Vidal, August, Voest, Emile, Wessels, Lodewyk F. A., van Tellingen, Olaf, Villanueva, Alberto, Bernards, René
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7308397/ https://www.ncbi.nlm.nih.gov/pubmed/32572029 http://dx.doi.org/10.1038/s41467-020-16952-9

Ejemplares similares

RUNX2/CBFB modulates the response to MEK inhibitors through activation of receptor tyrosine kinases in KRAS-mutant colorectal cancer
por: Šuštić, Tonći, et al.
Publicado: (2019)

Identifying mutant-specific multi-drug combinations using comparative network reconstruction
por: Bosdriesz, Evert, et al.
Publicado: (2022)

Comparative Network Reconstruction using mixed integer programming
por: Bosdriesz, Evert, et al.
Publicado: (2018)

PI3K Pathway in NSCLC
por: Martinez-Martí, Alex, et al.
Publicado: (2012)

Pemetrexed as second-line therapy for advanced non-small-cell lung cancer (NSCLC)
por: Felip, Enriqueta, et al.
Publicado: (2008)

A role for the unfolded protein response stress sensor ERN1 in regulating the response to MEK inhibitors in KRAS mutant colon cancers
por: Šuštić, Tonći, et al.
Publicado: (2018)

Correction to: A role for the unfolded protein response stress sensor ERN1 in regulating the response to MEK inhibitors in KRAS mutant colon cancers
por: Šuštić, Tonći, et al.
Publicado: (2021)

Next generation sequencing of triple negative breast cancer to find predictors for chemotherapy response
por: Lips, Esther H., et al.
Publicado: (2015)

MAP3K1 and MAP2K4 mutations are associated with sensitivity to MEK inhibitors in multiple cancer models
por: Xue, Zheng, et al.
Publicado: (2018)

Cancer genome: highlights of a Nature Medicine perspective
por: Voest, Emile
Publicado: (2016)

Predicting clinical benefit from everolimus in patients with advanced solid tumors, the CPCT-03 study
por: Weeber, Fleur, et al.
Publicado: (2017)

Targeting the RB-E2F pathway in breast cancer
por: Johnson, Jackie, et al.
Publicado: (2016)

High levels of chromosomal aberrations negatively associate with benefit to checkpoint inhibition in NSCLC
por: Frigola, Joan, et al.
Publicado: (2022)

A Delphi consensus panel about clinical management of early-stage EGFR-mutated non-small cell lung cancer (NSCLC) in Spain: a Delphi consensus panel study
por: Isla, Dolores, et al.
Publicado: (2022)

Targeted Therapies Development in the Treatment of Advanced Nonsmall Cell Lung Cancer
por: Gridelli, Cesare, et al.
Publicado: (2011)

Cross-species comparison of aCGH data from mouse and human BRCA1- and BRCA2-mutated breast cancers
por: Holstege, Henne, et al.
Publicado: (2010)

Interrelations between Patients’ Clinicopathological Characteristics and Their Association with Response to Immunotherapy in a Real-World Cohort of NSCLC Patients
por: Callejo, Ana, et al.
Publicado: (2021)

How fast-growing bacteria robustly tune their ribosome concentration to approximate growth-rate maximization
por: Bosdriesz, Evert, et al.
Publicado: (2015)

Evolutionary pressures on microbial metabolic strategies in the chemostat
por: Wortel, Meike T., et al.
Publicado: (2016)

PTEN Loss in E-Cadherin-Deficient Mouse Mammary Epithelial Cells Rescues Apoptosis and Results in Development of Classical Invasive Lobular Carcinoma
por: Boelens, Mirjam C., et al.
Publicado: (2016)

Safety of Tepotinib in Patients With MET Exon 14 Skipping NSCLC and Recommendations for Management
por: Veillon, Remi, et al.
Publicado: (2022)

Personalizing Therapy with Targeted Agents in Non-Small Cell Lung Cancer
por: Dienstmann, Rodrigo, et al.
Publicado: (2011)

Identifying subgroup markers in heterogeneous populations
por: de Ronde, Jorma J., et al.
Publicado: (2013)

Phase III, randomized, open-label study of durvalumab (MEDI4736) in combination with tremelimumab or durvalumab alone versus platinum-based chemotherapy in first-line treatment of patients with advanced/metastatic NSCLC: MYSTIC
por: Rizvi, Naiyer, et al.
Publicado: (2015)

The Cancer SENESCopedia: A delineation of cancer cell senescence
por: Jochems, Fleur, et al.
Publicado: (2021)

Dual MET and ERBB inhibition overcomes intratumor plasticity in osimertinib-resistant-advanced non-small-cell lung cancer (NSCLC)
por: Martinez-Marti, A, et al.
Publicado: (2017)

Avelumab in Combination With Cetuximab and Chemotherapy as First-Line Treatment for Patients With Advanced Squamous NSCLC
por: Andric, Zoran, et al.
Publicado: (2023)

Breast Cancer Subtype Specific Classifiers of Response to Neoadjuvant Chemotherapy Do Not Outperform Classifiers Trained on All Subtypes
por: de Ronde, Jorma J., et al.
Publicado: (2014)

Editorial: Multidisciplinary management of cancer patients with immune-related adverse events from checkpoint inhibitors
por: Riveiro-Barciela, Mar, et al.
Publicado: (2023)

Symptoms and Experiences with Small Cell Lung Cancer: A Mixed Methods Study of Patients and Caregivers
por: Bebb, D. Gwyn, et al.
Publicado: (2023)

Dynamic changes in circulating tumor DNA assessed by shallow whole‐genome sequencing associate with clinical efficacy of checkpoint inhibitors in NSCLC
por: Carbonell, Caterina, et al.
Publicado: (2023)

Advancing molecular tumour boards: highly needed to maximise the impact of precision medicine
por: van de Haar, Joris, et al.
Publicado: (2019)

Are health care professionals able to judge cancer patients' health care preferences correctly? A cross-sectional study
por: Wessels, Hester, et al.
Publicado: (2010)

TG4010 immunotherapy plus chemotherapy as first-line treatment of advanced non small cell lung cancer (NSCLC): Phase IIb results of the TIME trial
por: Nemunaitis, John, et al.
Publicado: (2015)

Somatic structural rearrangements in genetically engineered mouse mammary tumors
por: Varela, Ignacio, et al.
Publicado: (2010)

Intra- and inter-tumor heterogeneity in a vemurafenib-resistant melanoma patient and derived xenografts
por: Kemper, Kristel, et al.
Publicado: (2015)

Sorafenib synergizes with metformin in NSCLC through AMPK pathway activation
por: Groenendijk, Floris H, et al.
Publicado: (2015)

Genome-wide epigenetic profiling of breast cancer tumors treated with aromatase inhibitors
por: Nevedomskaya, Ekaterina, et al.
Publicado: (2014)

Approximating multivariate posterior distribution functions from Monte Carlo samples for sequential Bayesian inference
por: Thijssen, Bram, et al.
Publicado: (2020)

SMARCE1 suppresses EGFR expression and controls responses to MET and ALK inhibitors in lung cancer
por: Papadakis, Andreas I, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_rch691ikcf70av1iv9jhmb5fr0